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The Women's Health Initiative (WHI) was the first randomized trial to assess the 
overall risk and benefit of estrogen (0.625 mg/day conjugated equine estrogen) plus 
progestin (2.5 mg/day medroxyprogesterone-acetate) (EP) in healthy postmenopausal 
women with an intact uterus (1). The WHI designated invasive breast cancer as a primary 
adverse outcome based on observational data (1) obtained from prior studies (2, 3). These 
studies included a meta-analysis of estrogen replacement therapy's effect on breast 
cancer risk that concluded by indicating a need to determine if breast cancer risk is 
affected by progestin use (2) and another meta-analysis of estrogen and EP therapy which 
concluded that the uncertainty of EP therapy's risk for breast cancer had not been studied 
adequately (3). 
The hormone replacement therapy (HR T) component of the WHI clinical trial 
was designed to randomize 27,500 women for an average follow-up of approximately 9 
years (4). Statistical stopping rules for the trial were determined by using hypothetical 
sets of interim trial results (scenarios) after an average follow-up of6 years (5). Members 
of the Data and Safety Monitoring Committee (DSMC) reviewed the scenarios and made 
recommendations on whether or not to stop the trial (5). 
The WHI trial was stopped early after an average follow-up of 5.2 years because 
while the adverse effects of cardiovascular diseases remained within the monitoring 
boundaries, the invasive breast cancer test statistic exceeded the adverse effect stopping 
boundary and the risk exceeding the benefits was supported by the global index statistic 
(defined as the earliest occurrence of coronary heart disease, stroke, pulmonary 
embolism, invasive breast cancer, endometrial cancer, colorectal cancer, hip fracture, or 
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death from other causes) (1). The trial found that among 10,000 women taking EP 
compared with placebo, eight more might experience invasive breast cancers over a 
I-year period, representing a 26% increase in breast cancer risk (1). 
The WHI trial design was based on data available in 1991-1992 (1). Thus, we 
perfonned a systematic review and meta-analysis of the available published studies on 
the use of EP therapy and the risk of breast cancer in postmenopausal women that were 
accepted for publication prior to the publication of the WHI's results (1) in July of2002. 
Our analysis examines EP HR T and the risk of developing breast cancer associated with 
ever, recent, or past, and never use ofEP HRT. International studies were not included in 
the analysis since conjugated estrogens and medroxyprogesterone-acetate are primarily 
used in the US, whereas in Europe, oestradiol combined with testosterone-like progestins 
are commonly used (6). Our analysis of the literature detennines if more recent evidence 
in the literature could have had implications in guiding the stopping rules of the WHI 
trial. 
Methods 
Literature Search 
We searched PubMed (National Library of Medicine and the National Institutes 
of Health, Bethesda, MD) using combinations of keywords and some MeSH tenns for the 
keywords postmenopausal, estrogen, oestrogen, progestin, honnone replacement therapy, 
estrogen replacement therapy, oestrogen replacement therapy, breast cancer, and breast 
neoplasms. Evidence Based Medicine (EBM) Reviews from the Cochrane Central 
Register of Controlled Trials (CCTR) was searched using the keywords estrogen, 
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progestin, postmenopausal (variations of the word), breast cancer, and breast neoplasms. 
The American College of Physicians (ACP) Journal Club, Cochrane Database of 
Systematic Reviews (CDSR), and the Database of Abstracts of Reviews of Effects 
(DARE) from the EBM Reviews were searched using the keywords estrogen, progestin, 
variations of the word postmenopausal, breast cancer, and breast neoplasms. We searched 
the ACP Journal Club, CCTR, CDSR, DARE, and PubMed for meta-analyses or reviews 
from 2001 through 2005 in an effort to find publications prior to the WHI trial results 
published in 2002 that might be listed in the reference lists of these publications. We 
reviewed all titles and abstracts identified by our searches and the reference lists of 
relevant papers to broaden our search for additional articles. 
Inclusion Criteria 
Limits used for some of the searches included United States (US), clinical trial, 
English, and human. Publications were eligible for inclusion in the analysis if they were 
accepted for publication prior to the publication of the WHI's results (1) in July of2002, 
if the incidence of breast cancer was reported in postmenopausal women who used EP 
HRT, and if the study had a comparison group of never users (i.e., women who never 
used any combination of estrogen or progestin HRT (e.g., estrogen only or EP HRT)). 
Due to the limited availability of these published studies, we included studies into our 
analysis regardless of the type or dosage of estrogen or progestin used, or the number of 
days per month that progestin was used. 
Studies limited to Canadian women were excluded from the analysis. However, 
we did include one study in our analysis (7) that presented data from six US and one 
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Canadian city. We included this study in our analysis since we had a limited number of 
US studies and because Canadian data is often considered a proxy for US data. 
We found that many of the papers that were eligible for inclusion in the analysis 
covered the same cohort of women. For our analysis, we included the papers that reported 
longer follow-up of the study cohort, more person-years of observation, a larger study 
cohort, papers that placed more emphasis on EP HR T versus emphasis on other types of 
HRT, or papers that placed an emphasis on breast cancers associated with the usage of 
HRT rather than breast cancer associated with other risk factors (e.g., body mass index). 
Data Abstraction 
One author abstracted from each eligible study the first author's last name, year of 
publication, the relative risk (RR) estimate (i.e., adjusted odds ratio (OR), relative odds 
(RO), or relative risk), upper and lower 95% confidence intervals (CI), adjustments 
(adjusted or unadjusted RR estimates), study type (case-control or cohort), exposure 
(ever, recent, past), type of non-exposed subjects (never used any HRT, never used EP 
HRT), race (all, White, Black, Hispanic, non-Hispanic), cancer type (where invasive was 
defined as a minimum of 83% of cases included in the study were invasive, or the type of 
cancer was not specified), time period of first cases of diagnosed breast cancer 
(1960s-1970s, 1980s-1990s), and study location, included in the analysis since treatment 
practices in different parts of the US may affect the estimates. We considered analyzing 
breast cancer incidence versus mortality, but all eligible studies reported breast cancer 
incidence, not breast cancer mortality, therefore we were not able to compare incidence 
versus mortality. We defined recent use ofEP therapy as use within the last 2 years 
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immediately prior to the reference date and past use as use ofEP >2 years ago. Ever use 
was defined as recent plus past use. 
Four slight variations to our categorization of use included 1) the recent use data 
in the Schairer (8) study which provided an adjusted estimate for current users, not 
including use in the past 1-2 years, 2) the past use data in the Schairer (8) study which 
included data from 1-2 years, 3) the Newcomb (9) study in the past/never use analysis 
where past included use <5 years ago but separated out the current users, and 4) the Ross 
(10) study in the past/never use analysis which ascertained exposure histories up to one 
year before the reference date. 
There were two ways of classifying study locale, one for the ever/never results 
and one for the recent/never results, because all of the studies in the ever/never and 
recent/never analyses could not be grouped into a single type of locale descriptor that was 
suitable for all study locations. In the ever/never studies, Eastern US was defined as 
studies done in Eastern or Central time zones, and Western US was defined as studies 
that had some sites in the Western part as well as across the US. The recent/never studies 
were categorized according to studies conducted in one or two time zones in the US, or 
studies representative of cities across the US and/or one city in Canada. We were not able 
to classify study local for the past/never studies into two distinct study local descriptors 
that were suitable for all study locations due to the limited number of studies in this 
analysis. 
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Statistical Analysis 
Meta-analyses of three groupings of the published studies were performed: 1) 
ever/never EP HRT use, 2) recent/never EP HRT use, and 3) past/never EP HRT use. We 
categorized never use ofEP HRT into two categories: 1) women who never used any 
combination of estrogen or progestin HRT (i.e., estrogen only or EP HRT) during their 
lifetime, and 2) women who never used EP HRT (i.e., combined estrogen and progestin 
HRT). Some of the studies were used in more than one analysis because results within the 
particular study were categorized according to more than one of the three types of use 
(i.e., ever, recent, past). 
STATA Version 9.1 (Stata Corp., College Station, TX) was used to analyze the 
effect of EP HR T on the risk of breast cancer in postmenopausal women. The published 
studies reported ORs, RRs, or ROs for case-control studies and RRs for cohort studies, 
unless they reported only patient years of observation. We report all published ORs as 
RRs since the risk ratio and rate ratio are approximately equal over the follow-up period 
when the outcome is rare (11). 
We always abstracted adjusted RR estimates wherever they were available and 
made sure that they were properly adjusted for potential confounders. When adjusted 
estimates were not available, we computed unadjusted estimates ourselves using either 
Episheet (12), or the "metan" command in Stata when risk ratios, rather than rates or 
hazards, were reported in the published paper. 
We generated forest plots and used the "metabias" command in Stata as an 
indication of the potential for publication bias. We produced funnel plots and looked for 
evidence of funnel plot asymmetry visually and with the Begg and Mazumdar test (13), 
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the Egger et al. test (14), and the Duval and Tweedie trim and fill imputation method 
(15). We assessed overall heterogeneity of the literature by examining Cochrane Q P 
values from the "meta" analysis in Stata. 
We examined studies for heterogeneity with regard to specific study 
characteristics by performing stratified and random effects meta-regression (16) analyses 
using the restricted maximum likelihood method to estimate the among study variance. 
Associations between RR estimates and characteristics of studies and patients were 
analyzed. We inferred the standard errors of the log RR estimates from their 95% 
confidence intervals (17). 
Multi-variable meta-regression was not possible due to the small number of 
studies. All meta-regression results were transformed back to the original ratio scale. 
After transformation, each meta-regression coefficient estimated the ratio of the average 
RR in studies with one characteristic to the average RR in studies with another 
characteristic. These models quantified the degree of association between study 
characteristics and results. 
Study characteristics analyzed included adjustments, type of study, time of 
diagnosis, type of cancer, and study location in the ever/never analysis; and study type, 
time of diagnosis, and study location in the recent/never analysis. Meta-regression 
analyses were conducted only when there were at least two studies in each category of a 
study characteristic. 
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Results 
Of the ten eligible studies (7-10, 18-23) that met the inclusion criteria for the 
analysis (Table 1), six, five, and three studies were included in the ever/never, 
recent/never, and past/never analyses, respectively. One study (i.e., Li et al. (24)) was 
excluded from our analysis since it was the only study that presented results according to 
never use of the combined EP HR T regimen. 
Adjusted RR estimates were used for all analyses with the exception of the 
Gambrell study (18) in the ever/never analysis, and the Newcomb (9), Ross (10), and 
Schairer (8) studies in the past/never analysis, where only unadjusted RR estimates were 
available by using our calculations. We estimated the 22-year risk ratio from the one 
cohort study by Nachtigall (20). The characteristics of the individual studies and the 
analysis that they were used in are presented in Table 1. 
Ever/Never Use 
F our of the six estimates are below the null value in the direction of a reduced rate 
of breast cancer among EP users. Nachtigall (20) is by far the least precise estimate (i.e., 
furthest away from the null) (Figure 1). Some of these estimates are much more (and less) 
imprecise than others. The three least precise estimates are below the null and the three 
very precise estimates are close to the null. The estimate we computed from N achitgall' s 
study (20) is an exceedingly imprecise estimate. Inconsistent study results indicate 
heterogeneity . 
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Evidence of asymmetry was observed in the funnel plot, however some of the 
estimates were computed and are imprecise. The Begg and Egger tests (13, 14) both gave 
P=0.02, indicating evidence of funnel plot asymmetry, but the trim and fill analysis (15) 
imputed no hypothetically missing studies. The overall heterogeneity value ofP=O.OOI 
is indicative of a very heterogeneous literature. 
Fixed and random summary effects estimates are likely to be different due to 
imprecise estimates. Fixed stratified results are reported for most study characteristics, 
however random stratified results are reported for the study type, time of diagnosis, and 
study location study characteristics. Study characteristic analyses (Table 2) that included 
studies that were adjusted, specified invasive breast cancer, and had sites in the Western 
US as study characteristics suggest an increased risk of breast cancer of22%, 22%, and 
10%, respectively among ever users ofEP HRT. These study characteristics gave higher 
summary RRs on average than the study characteristics of study sites that gave 
unadjusted RR estimates, did not specifY the type of breast cancer, and were conducted in 
the Eastern US. When the unadjusted RR estimates, non-specified types of breast cancer, 
and studies conducted in the Eastern US were removed from the analysis, the summary 
RR indicated increased risks of breast cancer among women who ever used EP HRT. All 
95% CIs for summary RR estimates were wide. Our analysis suggests that the risk of 
developing breast cancer in women that ever used EP HR T was decreased in studies that 
reported unadjusted RR estimates, did not specifY the type of breast cancer, or had sites 
only in the Eastern part of the US by 82%,82%, and 53% respectively. 
The risk of developing breast cancer was negligible (1 %) in case-control studies 
and in studies with cases first diagnosed in the 1980s and 1990s. The risk of developing 
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breast cancer was increased in studies with adjusted RRs, case control studies, first cases 
of breast cancer diagnosed during the 1980s and 1990s, invasive breast, and studies that 
included results from states in the Western part of the US. These study characteristics 
increase the risk of developing breast cancer by 6YS, 2YS, 2YS, 6YS, and >2 times, 
respectively. A modest increase in the risk of developing breast cancer was observed in 
studies with unadjusted RRs, cohort studies, first cases of breast cancer diagnosed during 
the 1960s and 1970s, unspecified types of cancer, and studies that included results from 
states in the Eastern part of the US. All 95% CIs for the ratio ofRR estimates were wide. 
The homogeneity P values for the unadjusted studies and the studies with 
unspecified types of cancer were >0.2. This suggests homogeneity amongst the studies 
and that the studies do not differ a lot due to chance. The low P values (P<0.2) for all 
other study characteristics tested suggest heterogeneity amongst the studies and 
inconsistency due to chance. 
There is a lot of overall heterogeneity and several study characteristics have 
strong, but imprecise associations with study results. The funnel plot asymmetry mayor 
may not be due to biased literature; or the asymmetry may be due to one or more 
characteristics of studies that produce less precise estimates compared to studies that give 
more precise estimates. The study characteristics analysis lends support to the latter 
reason since it is hard to calculate estimates (i.e., Nachtigall (20), Gambrell (18)) and 
these values were further away from the null. Since the results were further away from 
the null and not reported by the authors, this is opposite of what we would expect if there 
was evidence of publication bias. In addition, two of the three imprecise and inverse 
associations (i.e., Nachtigall (20), Gambrell (18)) were unadjusted and did not specify the 
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type of cancer, therefore this analysis relies on the three more precise studies and all three 
are near the null. As a result, a single point summary estimate of this literature is 
contraindicated. Essentially, any study characteristic that separates two or all three of 
Nachtigall (20), Moorman (19), and Gambrell (18) from the others is going to show an 
association with an increased risk of breast cancer. 
Recent/Never Use 
All five estimates are above the null value in the direction of an increased rate of 
breast cancer among EP users (Figure 1). Some of these estimates are much more or less 
imprecise than others, with Kaufman (7) as the least precise estimate. Estimates from the 
three largest studies were more precise. These results indicate some homogeneity 
amongst the three largest studies. 
Evidence of asymmetry was observed in the funnel plot. There was also some 
evidence of funnel plot asymmetry with Begg (13) and Egger (14) P values of 0.2 and 
0.02, respectively. In addition, the trim and fill analysis (15) did impute one small, 
hypothetically missing study. However, the overall heterogeneity P value of 1.0 is 
indicative of a more homogeneous body of literature. 
Fixed and random summary effect estimates are likely to be similar due to a more 
homogeneous literature, thus fixed stratified results are reported for all study 
characteristics. Study characteristic analyses (Table 2) resulted in all examined study 
characteristics giving approximately the same summary RR. All 95% CIs for summary 
RR estimates were wide. All ratios ofRR estimates were 1.0, indicating an approximately 
identical probability of disease in women who were recently exposed and not exposed to 
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EP HRT. All study characteristic homogeneity P values were greater than 0.2, suggesting 
homogeneity amongst the studies and that the studies do not differ a lot due to chance. 
We did not perform a study characteristic analysis for the type of cancer study 
characteristic due to the lack of available studies for this study characteristic. 
Our analysis showed that there was not nearly as much overall heterogeneity to 
begin with, and none of the study characteristics were associated with the results. Overall, 
there was evidence of a symmetrical funnel plot, homogeneity P values were high, and all 
RR were equal to 1.0, warranting a summary estimate. The summary RR estimate for the 
recent-never results was 1.42 (95% cr, 1.26-1.60) representing a 40% increase in the risk 
of breast cancer among women who recently used EP HRT. This estimate was similar to 
.. 
the trim and fill estimate of 1.41 (95% cr 1.25-1.59). 
Past/Never Use 
All three estimates are above the null value in the direction of an increased rate of 
breast cancer among EP users (Figure 1). All estimates were computed, and some of 
these estimates are much more (and less) imprecise than others, with the Newcomb (9) 
estimate being the least precise estimate. Inconsistent study results are indicative of a 
heterogeneous literature. 
Evidence of asymmetry was observed in the funnel plot. Begg (13) and Egger 
(14) P values were 0.3 and 0.6, respectively and suggest funnel plot symmetry. The trim 
and fill method (15) imputed no hypothetically missing studies. The overall heterogeneity 
P value of 0.1 is indicative of heterogeneous literature. 
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Due to the limited number of studies in this analysis, study characteristics 
analyses were not performed and a single summary estimate was contraindicated. 
Discussion 
This systematic review suggests that there was limited information about the risk 
ofEP HRT and the risk of breast cancer in postmenopausal North American women prior 
to the publication of the WHI trial results. This analysis of the ten observational studies 
conducted prior to the publication of the WHI results suggest that there was consistent 
evidence of increased risk from using these preparations recently, as opposed to never, 
and inconsistent results for ever use, with the most precise estimates being very close to 
the null. 
Limitations of our analysis include restricting our analysis to studies accepted for 
publication prior to the publication of the WHI's results (1) in July of 2002, including 
only studies conducted in the US, not considering dosages or types ofEP HRT used in 
the studies, and the limited number of studies available for our analysis. 
We decided early in our analysis not to summarize the data into a single point 
summary estimate due to the limited amount of data and the difficulty assessing it for 
evidence of publication bias. Overall heterogeneity P values for the ever/never and the 
past/never analysis are suggestive of a heterogeneous body of literature, whereas the P 
value for the recent/never analysis was suggestive of a more homogeneous body of 
literature. As a result we decided after our analysis of the literature that a summary 
estimate was warranted for the recent/never analysis 
We could not pin down the heterogeneity of the ever/never results to a single 
study characteristic. Every one we looked at had some kind of association with the 
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studies' results and there is not much more that can be done with only six studies. For the 
recent/never analysis, there was not much evidence of heterogeneity to begin with and the 
associations with all the study characteristics were about as null as they could be 
expected to be in such a small number of studies. 
The WHI trial (1) reported a 26% increase in invasive breast cancer and suggested 
that the increased risk was consistent with the nonsignificant 27% increase reported after 
6.8 years of follow-up in the HERS study (25). The HERS study was not included in our 
meta-analysis. The WHI findings are consistent with other epidemiological data (26) that 
reported a 15% increase of breast cancer when EP was used <5 years and a 53% increase 
for use >5 years and our analysis that reports a 40% increase in the risk of breast cancer 
among recent users of EP HRT. 
Lack of evidence (2) and inconsistencies in the data (3) prevented calculation of a 
summary estimate in prior meta-analyses conducted in the early 1990s. However, the 
literature published through mid-2002, combined with different methodological 
techniques used in our analysis, allowed for a single summary estimate of the literature 
for recent EP HR T use. Our findings indicate that the literature in the early 1990s looks 
very different from the literature in mid-2002. 
Our ever/never and recent/never analysis results look different. Including past use 
in the ever use category may have diluted out the recent use. Past exposure is less 
relevant to risk and may result in misclassification of exposure. This may explain why 
there was no association amongst the three largest studies in the ever/never analysis and 
why there was a consistent, appreciable increase in risk in the recent/never analysis. Our 
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analysis of the literature resulted in a 40% relative increase in breast cancer in women 
that used EP HRT. This represents an absolute increase in risk of approximately 5% (27). 
Our findings do not imply that the stopping rules of the WHI trial (1) should have 
been changed based on the literature available in mid-2002, especially since the stopping 
rule that our analysis suggests is less conservative than the stopping rules that were 
applied during the trial. In addition, our analysis had limitations, thus we conclude that 
the WHI trial (1) was a very important trial to conduct since it was the first randomized 
controlled trial designed to assess the risk and benefit of EP HR T as opposed to using 
observational data and because it represented a larger cohort of postmenopausal women. 
The findings from the WHI should continue to inform relevant postmenopausal hormone 
therapy treatment options for women. 
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Table 1: Characteristics of Studies Containing Estimates of Breast Cancer Relative Risks According to the Use of Estrogen 
and Progestin Postmenopausal Hormone Replacement Therapy 
Publication Time of 
Analysis First Author Year Study Design Adjustment RR 95%CI Cancer Type Diagnosis Location 
EverlNever Gambrell (18) 1986 Cohort No 0.19 0.09-0.40 Not specified 1960s & 1970s Eastern USb 
Moorman (19) 2000 Case-control Yes 0.70 0.40-1.1 Invasivea 1980s & 1990s Eastern USb 
Nachtigall (20) 1992 Cohort No 0.04 0-0.68 Not specified 1960s & 1970s Eastern USb 
Newcomb (9) 2002 Case-control Yes 1.4 1.2-1. 7 Invasive 1980s & 1990s Eastern USb 
Schairer (8) 2000 Cohort Yes 1.3 1.0-1.6 Invasive 1960s & 1970s Western USc 
Stanford (21 ) 1995 Case-control Yes 0.90 0.70-1.3 Invasive 1980s & 1990s Western USc 
RecentlNever Chen (22) 2002 Case-control Yes 1.5 1.0-2.1 Invasive 1980s & 1990s 1-2 US time 
zones 
>-' Colditz (23) 1995 Cohort Yes 1.4 1.2-1. 7 Invasive 1960s & 1970s Across US 
\0 
Across USd Kaufman (7) 1991 Case-control Yes 1.7 0.90-3.6 Not specified 1980s & 1990s 
Newcomb (9) 2002 Case-control Yes 1.4 1.1-1.7 Invasive 1980s & 1990s 1-2 US time 
zones 
Schairer (8) 2000 Cohort Yes 1.4 1.1-1.9 Invasive 1960s & 1970s Across US 
PastlNever Newcomb (9) 2002 Case-control No 1.9 1.2-3.2 Invasive 1980s & 1990s NA 
Ross (10) 2000 Case-contro I No 1.2 0.99-1.4 Invasive 1980s & 1990s NA 
Schairer (8) 2000 Cohort No 1.1 0.73-1. 7 Invasive 1960s & 1970s NA 
a Where at least 83-89% of the cases were invasive. 
b Studies done in Eastern and Central time zones 
C Studies that have some sites in the Western part of the US. 
d Included the Canadian city of London, Ontario. 
Abbreviations: NA, not applicable; US, United States 
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Table 2. Analysis of Study Characteristics 
Analysis Study Number of Homogeneity 
characteristic Design studies P-value 
EverlNever Adjustment Unadjusted 2 0.28 
Adjusted 4 0.01 
Study design Cohort 3 0.00 
Case control 3 0.01 
Time of 1960s-1970s 3 0.00 
diagnosis 1980s-1990s 3 0.01 
Cancer type Not specified 2 0.28 
>83% of cases were invasive 4 0.01 
Location Eastern US 4 0.00 
Western USa 2 0.06 
RecentlNever Study design Cohort 2 0.97 
Case control 3 0.84 
Time of 1960s-1970s 2 0.97 
diagnosis 1980s-1990s 3 0.84 
Location 1-2 times zones in US 2 0.74 
Across USb 3 0.87 
a Includes some studies conducted throughout the United States involving some Western states. 
b One study included the Canadian city of London, Ontario. 
Abbreviations: CI, confidence limits; RR, relative risk; NA, not applicable; US, United States. 
SummaryRR Ratio ofRRs 
{95% CI} {95% CI} 
0.18 (0.09 - 0.36) 1.0 
1.22 (1.07 - 1.39) 6.5 (2.6-15.9) 
0.31 (0.05-1.79) 1.0 
1.01 (0.66-1.54) 2.5 (0.6-10.9) 
0.31 (0.05-1.79) 1.0 
1.01 (0.66-1.54) 2.5 (0.6-10.9) 
0.18 (0.09-0.36) 1.0 
1.22 (1.07-1.39) 6.5 (2.6-15.9) 
0.47 (0.16-1.33) 1.0 
1.10 (0.77-1.57) 2.2 (0.5-10.0) 
1.41 (1.19-1.66) 1.0 
1.43 (1.20-1.71) 1.0 (0.8-1.3) 
1.41 (1.19-1.66) 1.0 
1.43 (1.20-1.71) 1.0 (0.8-1.3) 
1.41 (1.18-1.70) 1.0 
1.42 (1.21-1.67) 1.0 (0.8-1.3) 
